AcuCort obtains regulatory approval to start bioequivalence study for the EU
AcuCort AB (Spotlight Stock Market: ACUC) today announces that the Czech State Institute for Drug Control, SUKL has approved the company’s application to conduct the bioequivalence study that is planned to be the basis for a registration application for the company’s innovative allergy drug Dexa ODF in the EU.In order to conduct clinical studies, AcuCort must gain approval from both the ethical committee and the regulatory authority in the country where the study will be performed. Together with the previously obtained approval from the ethical committee, today’s news means that the study